CMPX

Compass Therapeutics Stock Analysis

AI Rating

Fair
  • Quality2/10
  • Growth↓ 0/10
  • Value↑ 5/10
Compass Therapeutics sales and earnings growth
CMPX Growth
Low
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↓ 2.44%
  • FCF Y/Y↓ -20.47%
Compass Therapeutics gross and profit margin trends
CMPX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -42.42%
Compass Therapeutics net debt vs free cash flow
CMPX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Compass Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks